r2rtf
The clinical-report table engine learned Chinese, then learned to leave RTF entirely
Comparison · Analytics
DoseFinding vs patentsview
A side-by-side editorial comparison of DoseFinding and patentsview — release velocity, themes, recent moves, and the top alternatives to consider.
DoseFinding vs patentsview: at a glance
What is DoseFinding?
New stewardship at openpharma, then two releases adding the methods MCP-Mod was missing
DoseFinding implements MCP-Mod and related dose-response methodology for clinical trial design and analysis. In 2024 it changed hands — Marius Thomas took over as maintainer, Novartis was recorded as copyright holder and funder, and the package moved to the openpharma GitHub organisation with roxygen documentation and a proper NEWS file. The two releases since have added substantive methodology: model averaging for dose-response fitting in 1.3-1, and conditional and predictive power for interim analyses in 1.4-1.
What is patentsview?
Dormant for years, then rewritten wholesale when the API underneath it broke.
patentsview is an R client for the USPTO PatentsView API, and version 1.0.0 is less a feature release than a forced reconstruction: the upstream API introduced mandatory keys, renamed and re-nested its endpoints, and the package had to follow. Between 2017 and 2021 the release cadence was roughly annual and almost entirely defensive — wrapping examples so CRAN would not fail during API outages, patching URL encoding, adding throttling retries. The 1.0.0 work restores the package to parity with an API that no longer resembles the one it was written against.
DoseFinding vs patentsview: editorial side-by-side
DoseFinding
0.0ANALYTICS
New stewardship at openpharma, then two releases adding the methods MCP-Mod was missing
◆ Current state
DoseFinding implements MCP-Mod and related dose-response methodology for clinical trial design and analysis. In 2024 it changed hands — Marius Thomas took over as maintainer, Novartis was recorded as copyright holder and funder, and the package moved to the openpharma GitHub organisation with roxygen documentation and a proper NEWS file. The two releases since have added substantive methodology: model averaging for dose-response fitting in 1.3-1, and conditional and predictive power for interim analyses in 1.4-1.
◆ Where it's heading
The pattern before the handover was maintenance — R-devel compliance, a bug fix, a link. After it, each release carries a named methodological addition with an acknowledged contributor, plus documentation to match: a longitudinal analysis vignette shipped alongside the interim power work. Housekeeping continues underneath, mostly clearing deprecated ggplot2 interfaces, aes_string in one release and qplot in the next.
◆ Prediction
Given the last two releases each added one method with a supporting vignette, expect the next to follow the same shape. Both additions so far extend the package beyond fixed dose-response fitting, so adaptive and interim methodology is the more likely direction.
patentsview
0.0ANALYTICS
Dormant for years, then rewritten wholesale when the API underneath it broke.
◆ Current state
patentsview is an R client for the USPTO PatentsView API, and version 1.0.0 is less a feature release than a forced reconstruction: the upstream API introduced mandatory keys, renamed and re-nested its endpoints, and the package had to follow. Between 2017 and 2021 the release cadence was roughly annual and almost entirely defensive — wrapping examples so CRAN would not fail during API outages, patching URL encoding, adding throttling retries. The 1.0.0 work restores the package to parity with an API that no longer resembles the one it was written against.
◆ Where it's heading
The arc here is a client package whose roadmap is entirely dictated by an upstream service it does not control. Every release since 0.2.0 has been reactive — HTTPS migration, throttling, encoding fixes, and now a full breaking rewrite. The one forward-looking piece is retrieve_linked_data(), which follows HATEOAS links the API now returns, meaning the package is starting to navigate the API rather than just query fixed endpoints.
◆ Prediction
Expect the next releases to be small follow-ups against the reworked API — field list refreshes and error handling for endpoints that behave differently in practice than in the documentation. The entries do not show any independent roadmap, so anything beyond that would depend on further upstream API changes.
Alternatives to DoseFinding and patentsview
Other Analytics products tracked by Sparkpulse, ranked by recent ship velocity. Each card links to a full editorial trajectory and lets you pivot into a head-to-head comparison with either DoseFinding or patentsview.
webmockr
The stubbing library added httr2 support, then spent a year cutting itself free of everything else
crul
crul took mocking back from webmockr and made it a property of the client itself
dendroNetwork
Six releases, six identical bodies — the feed carries the package abstract instead of release notes
chattr
chattr deleted every LLM integration it had written and outsourced the lot to ellmer
cloudml
Six years since the last functional change, and Google renamed the service it wraps in the release before that
See all DoseFinding alternatives → · See all patentsview alternatives →
Recent activity from DoseFinding and patentsview
Latest ship moves from both products, interleaved chronologically. ⚡ = editorial spark.
- 6mo agopatentsviewRebuilt for PatentsView's new API: keys, nested endpoints ⚡
- 1y agoDoseFindingConditional and predictive power for interim analyses
- 1y agoDoseFindingModel averaging arrives for dose-response fitting ⚡
- 1y agoDoseFindingPackage moves to openpharma under new maintainership
- 2y agoDoseFindingCompliance update for R-devel
- 3y agoDoseFindingpowMCTBinCount bug fix
- 4y agopatentsviewMoves to HTTPS endpoints and handles API throttling
- 7y agopatentsviewVignettes dropped so CRAN builds survive API outages
- 8y agopatentsviewAPI examples wrapped in dontrun for CRAN stability
- 8y agopatentsviewcast_pv_data() converts returned columns to real types
- 9y agopatentsviewFirst release: query DSL for the PatentsView API
Frequently asked questions
What is the difference between DoseFinding and patentsview?
They serve adjacent needs but don't currently overlap on shipped themes. DoseFinding and patentsview are shipping at a similar cadence (velocity 0.0 vs 0.0, both within Sparkpulse's "active" band). See the at-a-glance table above for a side-by-side breakdown of velocity, recent sparks, and editorial themes.
Is DoseFinding better than patentsview?
Sparkpulse doesn't pick a winner — we score release velocity, not feature parity. DoseFinding and patentsview are shipping at a similar cadence (velocity 0.0 vs 0.0, both within Sparkpulse's "active" band). For your specific use case, the alternatives sections above list other Analytics products to evaluate alongside.
What are the best alternatives to DoseFinding?
Top DoseFinding alternatives in Analytics are ranked by recent ship velocity. Browse the "DoseFinding alternatives" section above for the current picks, or visit /alternatives/dosefinding for the full list with editorial commentary on each.
What are the best alternatives to patentsview?
Top patentsview alternatives in Analytics are ranked by recent ship velocity. Browse the "patentsview alternatives" section above for the current picks, or visit /alternatives/patentsview for the full list with editorial commentary on each.